Browsing by Subject "chronic myelogenous leukemia"
Now showing items 1-9 of 9
-
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
(Springer Nature, 2009-05-28)Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged ... -
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase cml patients treated with imatinib mesylate
(American Society of Hematology, 2004-01-15)We followed 141 patients treated with imatinib mesylate (>300 mg) for chronic-phase chronic myelogenous leukemia (CML) following failure of treatment with interferon. During 12 months from the start of imatinib mesylate ... -
Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
(Wiley-Blackwell, 2012-05-01)Eur J Clin Invest 2012; 42 (9): 10161026 Abstract Background Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukaemia (CML). Results from ongoing phase 3 trials with nilotinib ... -
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
(American Society of Hematology, 2011-04-05)Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated ... -
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase ii study
(Springer Nature, 2012-07-05)Nilotinib (Tasigna) is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant ... -
Nilotinib in patients with ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
(Springer Nature, 2011-11-11)Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase ... -
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
(Springer Nature, 2011-12-13)Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400mg of nilotinib was ... -
Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
(Springer Nature, 2012-11-06)The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients ... -
The impact of clonal evolution on response to imatinib mesylate (sti571) in accelerated phase cml
(American Society of Hematology, 2002-05-13)